drug
Zoryve
Marketedupdated 3mo agoby $ARQT Arcutis Biotherapeutics, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 20 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying Zoryve
- phase3Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
- phase3Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
- phase3Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
- phase3A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
- phase2A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
- phase3Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
- phase2A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
- phase3Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 5, 2026
54 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (68)
- Aug 19, 2042formulationUS 12453721
- Dec 3, 2041method-of-use (U-3773)US 11707454
- Dec 3, 2041method-of-use (U-3773)US 12329751
- Aug 25, 2037method-of-use (U-3408)US 11129818
- Aug 25, 2037method-of-use (U-3970)US 11129818
- Aug 25, 2037method-of-use (U-4301)US 11129818
- Aug 25, 2037method-of-use (U-3773)US 11129818
- Jun 7, 2037formulationUS 10940142
- Jun 7, 2037formulationUS 10940142
- Jun 7, 2037formulationUS 10940142
- Jun 7, 2037formulationUS 10940142
- Jun 7, 2037formulationUS 11793796
- Jun 7, 2037formulationUS 11793796
- Jun 7, 2037formulationUS 11793796
- Jun 7, 2037formulationUS 11793796
- Jun 7, 2037method-of-use (U-3748)US 11819496
- Jun 7, 2037method-of-use (U-4301)US 11819496
- Jun 7, 2037method-of-use (U-3773)US 11819496
- Jun 7, 2037method-of-use (U-3970)US 11819496
- Jun 7, 2037method-of-use (U-3773)US 11992480
- Jun 7, 2037method-of-use (U-3970)US 11992480
- Jun 7, 2037method-of-use (U-4301)US 11992480
- Jun 7, 2037method-of-use (U-3748)US 11992480
- Jun 7, 2037method-of-use (U-3748)US 12005051
- Jun 7, 2037method-of-use (U-3773)US 12005051
- Jun 7, 2037method-of-use (U-4301)US 12005051
- Jun 7, 2037method-of-use (U-3970)US 12005051
- Jun 7, 2037formulationUS 12005052
- Jun 7, 2037formulationUS 12005052
- Jun 7, 2037formulationUS 12005052
- Jun 7, 2037formulationUS 12005052
- Jun 7, 2037formulationUS 12011437
- Jun 7, 2037formulationUS 12011437
- Jun 7, 2037formulationUS 12011437
- Jun 7, 2037formulationUS 12011437
- Jun 7, 2037formulationUS 12016848
- Jun 7, 2037formulationUS 12016848
- Jun 7, 2037formulationUS 12016848
- Jun 7, 2037formulationUS 12016848
- Jun 7, 2037formulationUS 12042487
- Jun 7, 2037formulationUS 12042487
- Jun 7, 2037formulationUS 12042487
- Jun 7, 2037formulationUS 12042487
- Jun 7, 2037formulationUS 12220409
- Jun 7, 2037formulationUS 12220409
- Jun 7, 2037formulationUS 12220409
- Jun 7, 2037formulationUS 12220409
- Jun 7, 2037formulationUS 12257242
- Jun 7, 2037formulationUS 12257242
- Jun 7, 2037formulationUS 12257242
- Jun 7, 2037formulationUS 12257242
- Jun 7, 2037method-of-use (U-3970)US 12310956
- Jun 7, 2037method-of-use (U-4301)US 12310956
- Jun 7, 2037method-of-use (U-4203)US 12310956
- Jun 7, 2037method-of-use (U-3748)US 12310956
- Jun 7, 2037formulationUS 12336983
- Jun 7, 2037formulationUS 12336983
- Jun 7, 2037formulationUS 12336983
- Jun 7, 2037formulationUS 12336983
- Jun 7, 2037formulationUS 12390453
- Jun 7, 2037formulationUS 9884050
- Jun 7, 2037formulationUS 9884050
- Jun 7, 2037formulationUS 9884050
- Jun 7, 2037formulationUS 9884050
- Jun 7, 2037method-of-use (U-4301)US 9907788
- Jun 7, 2037method-of-use (U-3970)US 9907788
- Jun 7, 2037method-of-use (U-3408)US 9907788
- Jun 7, 2037method-of-use (U-3773)US 9907788
FDA exclusivities (5)
- Oct 4, 2028NSNS2.1y
- May 22, 2028I-969Indication (3y)1.8y
- Jul 9, 2027NSNS331d
- Dec 15, 2026NPNP125d
- Oct 5, 2026NPPNew Product (3y)54d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that